Actively Recruiting // Clinical Trials // Congenital Achromatopsia // Genetic mutation // Inherited Retinal Degeneration // Kimberly Stepien // Sep 30 2020
A Multiple-Site, Phase 1/2, Safety and Efficacy Trial of AGTC 402, a Recombinant Adeno-associated Virus Vector Expressing CNGA3, in Patients with Congenital Achromatopsia Caused by Mutations in the CNGA3 Gene
- Sponsor: Applied Genetic Technologies Corp
- Principal Investigator: Kimberly Stepien, MD
- Study Coordinator: Nickie Stangel
Study objective:
To evaluate the safety and efficacy of AGTC-402 administered to one eye by subretinal injection in individuals with achromatopsia caused by mutations in the CNGA3 gene.
Study design:
The study involves 12 visits the first year, and annual visits over the next 4 years. Subjects will be enrolled sequentially in to one of seven dosing groups. Subjects will either receive varying dose levels of study agent or the maximum tolerated dose.
Inclusion criteria:
- Male or female subjects with documented mutations in both alleles of the CNGA3 gene;
- Retinal disease consistent with a clinical diagnosis of achromatopsia;
- At least 18 years of age for Groups 1, 2, 3, 4, and 5 and at least 6 years of age for Groups 3a, 4a and 6;
- Able to perform tests of visual and retinal function;
- Visual acuity in the study eye not better than 55 ETDRS letters (Snellen equivalent 20/80) based on the average of two examinations at the baseline visit;
- Acceptable laboratory parameters;
- For females of childbearing potential: A negative pregnancy test within 2 days before administration of study agent.
Exclusion criteria:
- Best-corrected visual acuity difference between the two eyes of > 15 ETDRS letters (3 lines);
- Evidence of degenerative myopia in the study eye
Contact Nickie Stangel with questions: 608-263-8783. For more information about this study: visit clinicaltrials.gov